Acetazolamide NDC 70756-721

NDC codes

FDA NDC Directory

Product NDC (as listed)70756-721Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70756-0721Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70756-721-11	70756072111	100 TABLET in 1 BOTTLE (70756-721-11)Marketed from Nov 13, 2020
70756-721-99	70756072199	10 BLISTER PACK in 1 CARTON (70756-721-99) / 10 TABLET in 1 BLISTER PACKMarketed from May 15, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Acetazolamide
Generic name (nonproprietary): acetazolamide
Active ingredients: Acetazolamide — 250 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Lifestar Pharma LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214282
Marketing start: Nov 13, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Carbonic Anhydrase Inhibitors (Mechanism)Sulfonamides (Chemical structure)
Identifiers: Product ID 70756-721_be4d7d81-4fe9-4a54-a7c0-18f825eeba98SPL ID be4d7d81-4fe9-4a54-a7c0-18f825eeba98SPL set ID 0913db35-3f08-4d82-8394-486bd9a487c4RxCUI 197303, 197304UNII O3FX965V0I
Pharmacologic class: Carbonic Anhydrase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470756072111 followed by a unit qualifier and the quantity

Package 70756-0721-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 17, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214282

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214282
Product	Strength	Form · route	Labeler	Product NDC
Acetazolamide	Acetazolamide 125 mg/1	TabletOral	Bryant Ranch Prepack	63629-1194
Acetazolamide	Acetazolamide 250 mg/1	TabletOral	Bryant Ranch Prepack	63629-1195
Acetazolamide	Acetazolamide 125 mg/1	TabletOral	Bryant Ranch Prepack	72162-1978
Acetazolamide	Acetazolamide 250 mg/1	TabletOral	Bryant Ranch Prepack	72162-1979
Acetazolamide	Acetazolamide 125 mg/1	TabletOral	Lifestar Pharma LLC	70756-720